

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of</p> <p>Capon et al.</p> <p>Serial No.: To be assigned</p> <p>Filed: January 30, 2004</p> <p>For: ADHESON VARIANTS</p>	<p>Group Art Unit: To be assigned</p> <p>Examiner: To be assigned</p> <p>Confirmation No: To be assigned</p> <p>CUSTOMER NO: 09157</p> <hr/> <p><b>Express Mail No. EV 351931777 US</b>  <b>Mailed January 30, 2004</b></p>
---	---

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Patent Application  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[X] **37 CFR § 1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR § 1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR § 1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR § 1.114.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (\*) in the attached PTO-1449

Express Mail No. EV 351931777 US

form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 10/157,408, filed May 28, 2002 and relied upon in this application for an earlier filing date under 35 USC § 120.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

Date: January 30, 2004

By: 

Jeffrey S. Kubinec

Reg. No. 36,575

Telephone No. (650) 225-8228

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0444P1C7	Serial No.		
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Capon et al.			
				Filing Date 30 Jan 2004	Group		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	* 1	3,959,080	25.05.76	Orth et al.			
	* 2	4,002,531	11.01.77	Royer			
	* 3	4,055,635	25.10.77	Green et al.			
	* 4	4,301,144	17.11.81	Iwashita et al.			
	* 5	4,412,989	01.11.83	Iwashita, Y.			
	* 6	4,444,878	24.04.84	Paulus et al.			
	* 7	4,745,055	17.05.88	Schenk, D.			
	* 8	4,761,371	02.08.88	Bell et al.			
	* 9	4,766,106	23.08.88	Katre, N.			
	* 10	4,816,567	28.03.89	Cabilly et al.			
	* 11	4,879,211	07.11.89	Wang et al.			
	* 12	5,336,603	09.08.94	Capon et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes      No
	* 13	068,763	05.01.83	EPO			
	* 14	088,695	14.09.83	EPO			
	* 15	120,694	03.10.84	EPO			
	* 16	139,416	02.05.85	EPO			
	* 17	173,494	05.03.86	EPO			
	* 18	244,221	04.11.87	EPO			
	* 19	255,694	10.02.88	EPO			
	* 20	256,654	24.02.88	EPO			
	* 21	266,663	11.05.88	EPO			
	* 22	278,776	17.08.88	EPO			
	* 23	296,786	28.12.88	EPO			
	* 24	313,377	26.04.89	EPO			
	* 25	325,262	26.07.89	EPO			
	* 26	330,227	30.08.89	EPO			
	* 27	331,356	06.09.89	EPO			
	* 28	EP 319,815	14.06.89	EPO			
	* 29	WO 85/03947	12.09.85	PCT			
	* 30	WO 87/03600	18.06.87	PCT			
	* 31	WO 88/01304	25.02.88	PCT			
	* 32	WO 88/03559	19.05.88	PCT			
	* 33	WO 88/07376	06.10.88	PCT (ENGLISH ABSTRACT)			
Examiner					Date Considered		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0444P1C7	Serial No.			
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Capon et al.				
				Filing Date 30 Jan 2004	Group			
<b>FOREIGN PATENT DOCUMENTS</b>								
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes      No	
	* 34	WO 88/09344	01.12.88	PCT				
	* 35	WO 89/01940	09.03.89	PCT				
	* 36	WO 89/03221	20.04.89	PCT				
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>								
	* 37	Allaway et al., "Expression and Characterization of CD4-IgG <sub>2</sub> , a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates" <u>Aids Research and Retroviruses</u> 11(5):533-539 (1995)						
	* 38	Amster et al., "Synthesis of part of a mouse immunoglobulin light chain in a bacterial clone" <u>Nucl. Acids Res.</u> 8(10):2055-2065 (1980)						
	* 39	Anderson et al., "Regulatory Interactions Between Members of the Immunoglobulin Superfamily" <u>Immunology Today</u> 9(7 & 8):199-203 (1988)						
	* 40	Aruffo et al., "CD44 is the Principal Cell Surface Receptor for Hyaluronate" <u>Cell</u> 61:1303-1313 (1990)						
	* 41	Beauchamp et al., "A new procedure for the synthesis of polyethylene glycol-protein adducts; effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin, and $\alpha_2$ -macroglobulin" <u>Analytical Biochemistry</u> 131(1):25-33 (1983)						
	* 42	Blank et al., "Complete structure and expression in transfected cells of high affinity IgE receptor" <u>Nature</u> 337(6203):187-189 (1989)						
	* 43	Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984)						
	* 44	Byrn et al., "Biological Properties of a CD4 Immunoaderhin" <u>Nature</u> 344:667-670 (April 12, 1990)						
	* 45	Capon et al., "Designing CD4 Immunoaderhins for AIDS Therapy" <u>Nature</u> 337:525-531 (1989)						
	* 46	Chamow et al., "A Humanized, Bispecific Immunoaderhin-Antibody That Retargets CD3 <sup>+</sup> Effectors to Kill HIV-1-Infected Cells" <u>Journal of Immunology</u> 153:4268-4280 (1994)						
	* 47	Chaudhary et al., "Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin" <u>Proc. Natl. Acad. Sci. USA</u> 84:4538-4542 (1987)						
	* 48	Clark et al., "Peptide and nucleotide sequences for rat CD4 (W3/25) antigen: Evidence for derivation from a structure with four immunoglobulin-related domains" <u>Proc. Natl. Acad. Sci.</u> 84:1649-1653 (1987)						
	* 49	Clerici et al., "Effect of a Recombinant CD4-IgG on In Vitro T Helper Cell Function: Data From a Phase I/II Study of Patients with AIDS" <u>The Journal of Infectious Diseases</u> 168:1012-1016 (1993)						
	* 50	Estess et al., "Analysis of T-cell receptor structure and function using chimeric T-cell receptor/immunoglobulin molecules" <u>Journal of Cellular Biochemistry Supplement</u> 11(Part D, Abs. 331):258 (1987)						
	* 51	Falkner and Zachau, "Expression of mouse immunoglobulin genes in monkey cells" <u>Nature</u> 298:286-288 (1982)						
	* 52	Gascoigne et al., "Secretion of a Chimeric T-cell Receptor-immunoglobulin Protein" <u>Proc. Natl. Acad. Sci. USA</u> 84:2936-2940 (1987)						
	* 53	Gascoigne et al., "Secretion of chimeric T cell receptor-immunoglobulin fusion proteins" <u>Journal of Cellular Biochemistry Supplement</u> 11(Part D, Abs. 333):259 (1987)						
Examiner				Date Considered				

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0444P1C7	Serial No.
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Capon et al.	
				Filing Date 30 Jan 2004	Group
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
*	54	Goverman et al., "Chimeric T-cell receptor genes as tools in analyzing T-cell/target-cell interactions" <u>Journal of Cellular Biochemistry Supplement</u> 11(Part D, Abs. 334):259 (1987)			
*	55	Haak-Frendscho et al., "Human IgE Receptor $\alpha$ chain-IgG Chimera Blocks Passive Cutaneous Anaphylaxis Reaction In Vivo" <u>J. Immunol.</u> 151(1):351-358 (1993)			
*	56	Hakimi et al., "The $\alpha$ subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding" <u>Journal of Biological Chemistry</u> 265(36):22079-22081 (1990)			
*	57	Hashimoto et al., "Rearrangement and expression of T cell receptor genes in pre-T cells" <u>Journal of Cellular Biochemistry Supplement</u> 11(Part D, Abs. 434):278 (1987)			
*	58	"Human Immunodeficiency Virus Infection" <u>The Merck Manual of Diagnosis and Therapy</u> , Mark H. Beers and Robert Berkow, M.D., 17th edition, Whitehouse Station, N.J.:Merck Research Laboratories, Chapter 163, pps. 1312-1323 (1999)			
*	59	Ivars et al., "Expression of cloned T cell receptor genes" <u>Journal of Cellular Biochemistry Supplement</u> 11(Part D, Abs. 435):278 (1987)			
*	60	Johnson et al., "Correlation of T cell receptor structure and function" <u>Journal of Cellular Biochemistry Supplement</u> 11(Part D, Abs. 337):260 (1987)			
*	61	Kahn et al., "A Phase 1 Study of Recombinant Human CD4 Immunoglobulin G (rCD4-IgG) In Patients With HIV-Associated Immune Thrombocytopenic Purpura" (W.B. 2156) pps. 221 (1991)			
*	62	Kohler, G., "Immunoglobulin chain loss in hybridoma lines" <u>Proc. Natl. Acad. Sci. USA</u> 77(4):2197-2199 (1980)			
*	63	Linsley et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation" <u>Journal of Experimental Medicine</u> 173:721-730 (1991)			
*	64	Linsley et al., "CTLA-4 is a second receptor for the B cell activation antigen B7" <u>Journal of Experimental Medicine</u> 174:561-569 (1991)			
*	65	Littman DR, "The isolation and sequence of the gene encoding T8: a molecule defining functional classes of T lymphocytes" <u>Cell</u> 40(2):237-246 (1985)			
*	66	Littman DR, "The structure of the CD4 and CD8 genes" <u>Annual Review of Immunology</u> 5:561-584 (1987)			
*	67	Maddon et al., "The Isolation and Nucleotide Sequence of a cDNA Encoding the T Cell Surface Protein T4: A New Member of the Immunoglobulin Gene Family" <u>Cell</u> 42:93-104 (1985)			
*	68	Maddon et al., "The T4 Gene Encodes the AIDS Virus Receptor and Is Expressed in the Immune System and the Brain" <u>Cell</u> 47:333-348 (1986)			
*	69	Maddon P. et al., "Structure and expression of the human and mouse T4 genes" <u>Proc. Natl. Acad. Sci. USA</u> 84(24):9155-9159 (1987)			
*	70	McDougal et al., "Binding of HTLV-III/LAV to T4 <sup>+</sup> Cells by a Complex of the 110k Viral Protein and the T4 Molecule" <u>Science</u> 231:382-385 (1986)			
*	71	McDougal et al., "The T4 Glycoprotein Is a Cell-Surface Receptor for the AIDS Virus" <u>Molecular Biology of Homosapiens</u> (Cold Spring Harbor Symposia on Quantitative Biology), New York:CSHL Vol. LI (1986)			
*	72	Miller, Larry et al., "Expression of high-affinity binding of human immunoglobulin E by transfected cells" <u>Science</u> 244:334-336 (1989)			
*	73	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)			
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P0444P1C7	Serial No.
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Capon et al.	
				Filing Date 30 Jan 2004	Group
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
* 74	Morrison et al., "Genetically Engineered Antibody Molecules and Their Application" <u>Biological Approaches to the Controlled Delivery of Drugs</u> , Annals of the New York Academy of Sciences, New York, New York: The New York Academy of Sciences Vol. 507:187-198 (1987)				
* 75	Morrison et al., "Transfer and expression of immunoglobulin genes" <u>Annual Review of Immunology</u> 2:239-256 (1984)				
* 76	Morrison, J., "Sequentially derived mutants of the constant region of the heavy chain of murine immunoglobulins" <u>J. of Immunology</u> 123(2):793-800 (1979)				
* 77	Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985)				
* 78	Murre et al., "Biochemical and functional analyses of a secreted H-2Ld molecule" <u>Molecular &amp; Cellular Biology</u> 6:1315-1319 (1986)				
* 79	Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984)				
* 80	Oi et al., "Chimeric Antibodies" <u>BioTechniques</u> 4(3):214-221 (1986)				
* 81	Osborn, L. et al., "Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes" <u>Cell</u> 59:1203-1211 (1989)				
* 82	Peterson, A.S., "Genetic analysis of CD2/LFA-3 and CD4/HIV interactions" (thesis), Harvard University, Chapter 1, (1988)				
* 83	Putney et al., "HTLV-III/LAV neutralizing antibodies to an E.coli" <u>Science</u> 234:1392-1395 (1986)				
* 84	Rose and Bergmann, "Expression from Cloned cDNA of Cell-Surface Secreted Forms of the Glycoprotein of Vesicular Stomatitis Virus in Eucaryotic Cells" <u>Cell</u> 30:753-762 (1982)				
* 85	Rosenblum et al., "Modification of human leukocyte interferon pharmacology with a monoclonal antibody" <u>Cancer Research</u> 45:2421-2424 (1985)				
* 86	Salzawa et al., "The CD4 molecule is associated with the T-cell receptor" <u>Journal of Cellular Biochemistry Supplement</u> 11(Part D, Abs. 421):273 (1987)				
* 87	Schacker et al., "The Effects of High-Dose Recombinant Soluble CD4 on Human Immunodeficiency Virus Type 1 Viremia" <u>The Journal of Infectious Diseases</u> 169:37-40 (1994)				
* 88	Seed B., "An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2" <u>Nature</u> 329:840-842 (1987)				
* 89	Sharon et al., "Expression of a V <sub>H</sub> C <sub>K</sub> chimaeric protein in mouse myeloma cells" <u>Nature</u> 309:364-367 (1984)				
* 90	Shearer et al., "Transport of Recombinant Human CD4-Immunoglobulin G Across the Human Placenta: Pharmacokinetics and Safety in Six Mother-Infant Pairs in AIDS Clinical Trial Group Protocol 146" <u>Clinical and Diagnostic Laboratory Immunology</u> pps. 281-285 (1995)				
* 91	Sleckman et al., "Expression and function of CD4 in a murine T-cell hybridoma" <u>Nature</u> 328(6128):351-353 (1987)				
* 92	Smith et al., "Blocking of HIV-1 Infectivity by a Soluble, Secreted Form of the CD4 Antigen" <u>Science</u> 238:1704-1707 (1987)				
* 93	Springer and Strominger, "Detergent-soluble HLA antigens contain a hydrophilic region at the COOH-terminus and a penultimate hydrophobic region" <u>Proc. Natl. Acad. Sci. USA</u> 73(7):2481-2485 (1976)				
Examiner				Date Considered	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

